PublisherBMJ Publishing Group
MetadataShow full item record
DescriptionAntibiotic development may finally be picking up pace, with 11 new drugs approved in the past decade, four in 2014 alone, with the help of new legislation. But in this first installment of a series on antibiotics, Peter Doshi asks why authorities are approving drugs with little evidence they do anything to tackle the problem of antimicrobial resistance.
CitationDoshi, P. (2015). Speeding new antibiotics to market: a fake fix? BMJ 2015;350:h1453. DOI: https://doi.org/10.1136/bmj.h1453
Keywordqualified infectious disease product (QIDP)
Drug Resistance, Microbial
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/6601
- Antibiotic resistance: An infectious arms race.
- Authors: Hede K
- Issue date: 2014 May 1
- Authors: Corey GR, Stryjewski ME, Weyenberg W, Yasothan U, Kirkpatrick P
- Issue date: 2009 Dec
- Anti-infective drug development for MRSA.
- Authors: Daniel A
- Issue date: 2014
- Wisdom of Microbial Pathogens: A Novel Approach to Develop Antimicrobials Against Methicillin-Resistant Staphylococcus aureus.
- Authors: Kumar M
- Issue date: 2016 Apr
- First vanguard anti-MRSA agent approved.
- Authors: Fox JL
- Issue date: 2014 Jul